Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The company’s AATD discontinuation is the right decision and alleviates Intellia’s financing overhang, but the firm expects investors to question the timing of that decision with Phase 1 trial having just started, the analyst tells investors in a research note. The firm also continues to see Intellia shares as undervalued but warns that this week’s news may pr

Yahoo | January 11, 2025

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The discontinuation of the Alpha-1 Antitrypsin Deficiency program “makes sense” given the changing landscape, the analyst tells investors. Wells continues to think ATTR amyloidosis with cardiomyopathy is the main value driver and sees quick enrollment in the Phase 3 trial as a promising sign of patient acceptance of gene editing. Published first on TheFly – th

Yahoo | January 11, 2025

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

On Thursday, Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively. Intellia prioritized NTLA-2002 and nex-z while discontinuing the NTLA-3001 program and other early-stage initiatives. The reorganization will result in a 27% workforce reduction and a projected $8 million restructuring char

Yahoo | January 10, 2025

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

Yahoo | January 10, 2025

Intellia to stop work on rare disease therapy, lay off staff

The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

Yahoo | January 10, 2025

Intellia to cut 27% of workforce, discontinue NTLA-3001

More on Intellia Therapeutics

• Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
• Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
• Seeking Alpha | January 9, 2025

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study evaluating NTLA-2002 for HAE to complete enrollment in the second half of 2025; Company plans to submit a Biologics License Application in the second half of 2026More than 550 patients expected to be enrolled by year end within the ongoing MAGNITUDE study for nex-z in ATTR-CM – the progra

Yahoo | January 9, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for 23,155 shares of Intellia’s common stock,

Yahoo | January 6, 2025

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […]

Yahoo | December 30, 2024

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […]

Yahoo | December 29, 2024